-
In order to accelerate transformation, traditional pharmaceutical companies and Biotech cooperation mergers and acquisitions have become the norm!
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];Recently, another traditional pharmaceutical company and Biotech announced a merger and acquisition!
js?cdnversion='+~(-new Date()/36e5)];Recently, another traditional pharmaceutical company and Biotech announced a merger and acquisition!
js?cdnversion='+~(-new Date()/36e5)];Recently, another traditional pharmaceutical company and Biotech announced a merger and acquisition!
-
In 2023, the pace of mergers and acquisitions by multinational pharmaceutical companies may accelerate, targeting two hundred billion US dollar markets
Time of Update: 2023-02-01
Looking back on 2022, although the popularity of acquisitions in the pharmaceutical industry has decreased compared with the previous year, it is still remarkable. According to the 2022 pharmaceutica
-
The mergers and acquisitions of listed companies are hot, and there are 3 pharmaceutical companies in 1 day!
Time of Update: 2023-01-06
On the same day, Tailong Pharmaceutical issued an announcement on the participation of the company's wholly-owned subsidiary in the establishment of pharmaceutical industry funds and related party transactions, and the company's wholly-owned subsidiary Tailong Health intends to invest 10 million yuan to establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
-
The mergers and acquisitions of listed companies are hot, and there are 3 pharmaceutical companies in 1 day!
Time of Update: 2023-01-06
On the same day, Tailong Pharmaceutical issued an announcement on the participation of the company's wholly-owned subsidiary in the establishment of pharmaceutical industry funds and related party transactions, and the company's wholly-owned subsidiary Tailong Health intends to invest 10 million yuan to establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
-
Multinational pharmaceutical companies set off a wave of rare disease mergers and acquisitions
Time of Update: 2022-12-30
First, there are about 300 million patients with rare diseases in the world, and there are huge commercial interests in the market Due to the significant characteristics of small patient population, difficult drug research and development, and high cost, the rare disease track has always been a well-known "unpopular" and niche track, unlike anti-tumor, autoimmune and other popular tracks, attracting many pharmaceutical companies to compete and fight fiercely.
-
How to solve the financing difficulty? Pharmaceutical companies have "huddled together", and 235
Time of Update: 2022-11-15
Since the end of 2021, the biopharmaceutical industry has generally faced a slowdown in financing and cooperation, in addition, in the innovative drug track, the current homogenization of innovative drug research and development is more serious, coupled with the new medical reform environment background of tightening medical insurance control fees and centralized procurement and price reduction, in order to survive the cold winter, many pharmaceutical companies have "huddled together" through mergers and acquisitions and restructuring in 2022.
-
Biomedical M&A will be active in 2022, and local pharmaceutical companies will increase their mergers and acquisitions of overseas companies!
Time of Update: 2022-10-25
For example, in October, Kyushu Pharmaceutical announced that it had decided to change the 185 million yuan raised in the fundraising and investment project to acquire 100% of Sandoz Zhongshan Pharmaceutical Factory and increase its capital.
-
The merger and acquisition of Kailai Ying and Zhongsheng Pharmaceutical have encountered obstacles
Time of Update: 2022-10-12
On the evening of June 23, Zhongsheng Pharmaceutical announced that it had reached a merger agreement and plans to acquire all outstanding common shares of F-star, a NASDAQ-listed company, for a total consideration of $161 million, or $7.
-
The United States may tighten cross-border mergers and acquisitions of pharmaceutical companies, and there will be no winners after the gunshots
Time of Update: 2022-10-02
On September 15, the Biden administration signed a new policy to tighten cross-border biopharmaceutical mergers and acquisitions, requiring the Committee on Foreign Investment in the United States to strengthen risk reviews of biopharmaceuticals and biotechnology.
-
The pharmaceutical industry is active in mergers and acquisitions, and at the end of September
Time of Update: 2022-10-01
Since September this year, mergers and acquisitions in the pharmaceutical industry have been active, including Darentang's proposed acquisition of no more than 11. 9686 million shares of Keju Biologic
-
Heard that large mergers and acquisitions will hurt the R&D output rate of pharmaceutical companies?
Time of Update: 2022-09-09
In addition, in earlier years, when Biotech's biopharmaceuticals were still considered "high-risk" varieties, large pharmaceutical companies would face a situation of choosing between biological drugs and small molecules in the same category of projects after acquiring them.
-
131 million! At the end of August, another pharmaceutical company launched a merger and acquisition
Time of Update: 2022-09-08
On August 29, Jiuqiang Bio announced that the company and Xinyu Yuanlang Management Consulting Partnership (hereinafter referred to as "Yuanlang Management") signed an equity transfer agreement on August 29, 2022, and about 131 million yuan was transferred to Fuzhou Maixin Biotechnology Development Co.
-
Mergers and acquisitions have become an important part of the strategic layout of pharmaceutical equipment companies!
Time of Update: 2022-09-06
According to statistics, judging from the date of the first announcement and excluding transaction failure cases, as of August 23 this year, a total of 1,531 company mergers and acquisitions have occurred in the A-share market, an increase of 23.
-
Listed pharmaceutical companies launched a wave of mergers and acquisitions: more than 170 mergers
Time of Update: 2022-08-30
Huadong Pharmaceutical announced on August 9 that its wholly-owned subsidiary, Sino-US Huadong, will invest a total of no more than 396 million yuan, and obtain 60% of the equity of Huaren Technology in the form of capital increase and share transfer, becoming its controlling shareholder.
-
The pace of mergers and acquisitions in the biopharmaceutical industry has accelerated
Time of Update: 2022-08-30
Sihuan Pharmaceutical announced in January that its subsidiary Yaozhong International has acquired the entire equity of Genesis Biosystems in the United States, further expanding the company's medical beauty product pipeline .